The winding journey of biotech capital raising: deciphering the jargon

Nicholas Frame,Michael Casasanta,Oded Ben-Joseph
DOI: https://doi.org/10.1016/j.tibtech.2023.06.011
Abstract:Ensuring biotech companies are sufficiently capitalized to propel innovation and development remains a central focus for management. In this article, we draw on our broad perspective interacting with venture capitalists to offer thoughts on investor feedback. Understanding venture capitalists' mindsets and investment theses will increase the probability of securing needed capital.
What problem does this paper attempt to address?